Composition for constructing organoid based on clinical puncture sample of ovarian cancer and construction method
By providing suitable compositions and construction methods, the steps of collagenase dissociation of tissues are avoided, and the problem of cell damage in organoid construction in ovarian cancer puncture samples is solved, and efficient and high-quality organoid construction is achieved.
Patent Information
- Application Number
- CN202411241194.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-05
- Publication Date
- 2024-12-03
AI Technical Summary
Prior art When constructing organoids in ovarian cancer puncture samples, collagenase dissociates tissues resulting in cell damage and dead cells, affecting the yield and quality of organoids.
Provide a composition based on clinical puncture samples of ovarian cancer, including sample preservation solution and culture medium, clean the samples through the cleaning solution, and mix them thoroughly with the cell suspension to form organoids, avoiding the step of collagenase dissociation of tissues. , reducing cell damage.
It has achieved rapid and efficient construction of a large number of ovarian cancer organoids, which has improved the construction efficiency and number of organoids in the puncture sample, reduced cell damage, and improved the quality of organoids.
Smart Images

Figure CN119060940A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of organoid culture, and in particular to a composition for constructing organoids based on clinical puncture samples of ovarian cancer, and also to a method for constructing organoids using the composition. Background Art
[0002] Organoids are a type of 3D cell culture model. Since the technology was created by Hans Clevers and others in 2009 because of its 3D structure, it is closer to human biology. As scientists continue to delve deeper into organoid technology, 3D organoid model technology can further achieve a more successful personalized model of tumor tissue compared to 2D cell culture technology, thereby realizing the screening of personalized drug regimens.
[0003] Ovarian cancer is the eighth leading cause of cancer death in women. In my country, the annual incidence of ovarian cancer (OC) ranks third among female reproductive system tumors, after cervical cancer and uterine body malignant tumors, and is on the rise year by year. Its case fatality rate ranks first among female reproductive tract malignant tumors. It is a malignant tumor that seriously threatens women's health, and it is highly malignant and prone to metastasis. At present, 70% of patients with epithelial ovarian cancer relapse within three years after initial treatment. The increase in the number of recurrences and the gradual shortening of the intervals cause patients to change from chemotherapy sensitivity to drug resistance and eventually lead to treatment failure. Ovarian malignancies include a variety of pathological types, among which the most common is epithelial ovarian cancer (EOC), which accounts for about 80% of ovarian malignancies, followed by malignant germ cell tumors and sex cord stromal tumors, accounting for about 10% and 5% respectively.
[0004] Different histological types of ovarian cancer show different types of metabolic changes, including chemoresistant, chemosensitive, highly invasive and weakly invasive cells. Therefore, confirming the patient's pathological classification is of great significance for clinical medication. Obtaining biopsy specimens is an effective way to confirm case classification. There are many ways to obtain biopsy specimens, including laparoscopic surgery, laparotomy, and ultrasound-guided core-needle biopsy (CNB). Laparoscopic surgery and laparotomy require general anesthesia and are very traumatic. Ultrasound-guided core-needle biopsy is currently the most popular and practical tissue sampling method in clinical application. It has good accessibility and operability, low risk and trauma, and relatively low requirements for the patient's general condition. It is increasingly widely used in clinical application, but the tumor samples obtained by puncture are much lower than those obtained by laparoscopic surgery and laparotomy.
[0005] At present, the construction technology of ovarian cancer organoids with large tissue volume is relatively mature. Most of them are obtained by dissociating tissues with various types of collagenase to obtain primary ovarian cancer cells. However, due to the small size of the puncture sample, the collagenase has a violent enzymatic reaction during enzymatic hydrolysis, which causes great damage to the cells and easily produces a large number of dead cells. Therefore, when collagenase is used to process the puncture sample, a large number of primary cells will be lost, affecting the subsequent organoid production. Based on this, it is particularly important to establish a method for constructing organoids from ovarian cancer puncture samples. Summary of the invention
[0006] In view of this, one of the objects of the present invention is to provide a composition for constructing organoids based on clinical puncture samples of ovarian cancer; a second object of the present invention is to provide a method for constructing organoids using the composition.
[0007] In order to achieve the above object, the present invention provides the following technical solutions:
[0008] 1. A composition for constructing organoids based on clinical puncture samples of ovarian cancer, the composition comprising a sample preservation solution and a sample culture medium;
[0009] The components of the sample preservation solution are as follows: 1-20 μM Necrostatin-1, 15-40 mM GlutaMAX, 0.5-3% penicillin-streptomycin-amphotericin B, and the balance is Advanced DMEM / F12;
[0010] The components of the sample culture medium are as follows: 0.5-3mM Sodium Pyruvate, 10-50mM HEPES, 10-50mM GlutaMAX, 100-300μg / mL Primocin, 10-200nM 17-βestradiol, 200-1000ng / mL Hydrocortisone, 1-10μM A83-01, 1-10μM Nicotinamide, 5-30mL / L N-2supplement, 5-30mL / L B-27supplement, 1-3mM N-acetylcysteine, 0.1-2μM Adezmapimod, 5-100ng / mL EGF, 10-200ng / mL FGF-10, 50-200ng / mL Noggin, 50-250ng / mL R-spondin1, 20-200 ng / mL Heregulin-β-1, 50-500 ng / mL Wnt3a, 2-20 μM Forskolin, 5-20 μM Y-27632, 0.5-3% Penicillin-Streptomycin-Amphotericin B, the balance is Advaced DMEM / F12.
[0011] Preferably, the present invention further comprises a sample cleaning solution, wherein the concentrations of the components of the cleaning solution are as follows: 0.5-3% penicillin-streptomycin-amphotericin B, 0.05-0.5 mg / mL DNaseⅠ, 1-5 mg / mL Dispase II, 5-20 μM Y-27632, and the remainder is 1×DPBS.
[0012] Preferably, the components of the sample preservation solution are as follows: 1-20 μM Necrostatin-1, 15-40 mM GlutaMAX, 0.5-3% penicillin-streptomycin-amphotericin B, and the balance is Advanced DMEM / F12.
[0013] Preferably, the components of the sample culture medium are as follows: 1mM Sodium Pyruvate, 10-25mM HEPES, 20-30mM GlutaMAX, 100-200μg / mL Primocin, 10-20nM 17-βestradiol, 500ng / mL Hydrocortisone, 3-5μM A83-01, 5μM Nicotinamide, 10mL / L N-2supplement, 20mL / L B-27supplement, 1.25mM N-acetylcysteine, 0.5-1μM Adezmapimod, 20ng / mL EGF, 100-200ng / mL FGF-10, 100-200ng / mL Noggin, 50-250ng / mL R-spondin1, 50ng / mL Heregulin-β-1, 100ng / mL Wnt3a, 5-10μM Forskolin, 10 μM Y-27632, 1% penicillin-streptomycin-amphotericin B, the balance is Advaced DMEM / F12.
[0014] 2. A method for constructing an organoid using the composition, the specific method being as follows:
[0015] (1) After taking an ovarian cancer biopsy sample from the body, the sample is washed with a cleaning solution and then preserved with a preservation solution;
[0016] (2) staining the preserved sample with trypan blue staining solution, removing the stained non-living cell tissue, transferring the unstained puncture sample to the sample cleaning solution, shaking and cleaning, changing the cleaning solution during the process, and collecting the cleaning solution at the same time;
[0017] (3) centrifuging the collected washing solution and collecting the precipitate at the bottom of the tube;
[0018] (4) After washing, collect the loose and soft tumor sample by centrifugation and filter it with the precipitate obtained in step (3) through a 100 μm filter;
[0019] (5) Centrifuge and discard the supernatant, collect the sample precipitate, add the sample culture medium to form a cell suspension, mix it thoroughly with Matrigel, and drip it into the well plate; let it stand and culture to allow the matrix gel to fully solidify, then add the sample culture medium and culture it for 24 hours, then add the sample culture medium without Y-27632, change the medium every 3 days, and culture until ovarian cancer organoids are formed.
[0020] Preferably, in step (1), after the puncture biopsy sample is removed from the body, the sample is cleaned with a cleaning solution 5 times the sample volume, and then transferred to a sample preservation solution 10 times the sample volume, and transported at a cold chain of 0-8°C.
[0021] Preferably, in step (2), the concentration of the trypan blue staining solution is 0.4% and the staining time is 1 min.
[0022] Preferably, in step (2), the shaking cleaning is performed at 25° C., 200 rpm, for 60-90 min, and the sample cleaning solution is replaced every 5 min.
[0023] Preferably, in step (4) and step (5), the centrifugation is performed at 500×g, 4° C., for 10 min.
[0024] The beneficial effects of the present invention are as follows: the present invention provides a composition for constructing organoids based on clinical ovarian cancer puncture samples. The composition has a reasonable formula and can quickly and efficiently construct a large number of ovarian cancer organoids from ovarian cancer puncture samples without the need for separate digestion and enzymatic hydrolysis, thereby avoiding the problem of violent enzymatic hydrolysis reaction of collagenase during enzymatic hydrolysis, causing great damage to cells, and easily generating a large number of dead cells, which affects the subsequent yield of organoids. Compared with traditional organoid construction technology, the construction efficiency and quantity of organoids from ovarian cancer puncture samples are improved. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] In order to make the purpose, technical solution and beneficial effects of the present invention clearer, the present invention provides the following drawings for illustration:
[0026] Figure 1 The morphology of the organoids in Example 1 after 3 and 10 days of culture (1-1: morphology of organoids after 3 days of culture; 1-2: morphology of organoids after 10 days of culture);
[0027] Figure 2 The morphology of the organoids in Example 2 after 3 and 10 days of culture (2-1: morphology of organoids after 3 days of culture; 2-2: morphology of organoids after 10 days of culture);
[0028] Figure 3 The morphology of the organoids in the comparative example after 3 days and 10 days of culture (3-1: morphology of organoids after 3 days of culture; 3-2: morphology of organoids after 10 days of culture). DETAILED DESCRIPTION
[0029] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0030] Example 1
[0031] The culture medium and cleaning solution used in this example are as follows:
[0032] (1) An ovarian cancer biopsy specimen preservation solution, comprising the following components: 10 μM Necrostatin-1, 20 mM GlutaMAX, and 2% penicillin-streptomycin-amphotericin B, wherein the above components are dissolved in Advanced DMEM / F12, prepared before use, and temporarily stored or transported at 0-8°C.
[0033] (2) An ovarian cancer biopsy sample cleaning solution, the cleaning solution comprising the following components: 2% penicillin-streptomycin-amphotericin B, 0.2 mg / mL DNaseⅠ, 3 mg / mL Dispase II, 10 μM Y-27632, the above components are dissolved in 1×DPBS and prepared before use.
[0034] (3) An ovarian cancer biopsy sample culture medium, the culture medium comprising the following components: 1% penicillin-streptomycin-amphotericin B, 1mM Sodium Pyruvate, 25mM HEPES, 20mM GlutaMAX, 100μg / mL Primocin, 20nM 17-βestradiol, 500ng / mL Hydrocortisone, 5μM A83-01, 5μM Nicotinamide, 10mL / L N-2supplement, 20mL / L B-27supplement, 1.25mM N-acetylcysteine, 0.5μM Adezmapimod, 20ng / mL EGF, 100ng / mL FGF-10, 100ng / mL Noggin, 250ng / mL R-spondin1, 50ng / mL Heregulin-β-1, 100ng / mL Wnt3a, 5μM Forskolin, 10μM Y-27632, the above components were dissolved in AdvancedDMEM / F12;
[0035] (4) An ovarian cancer biopsy sample culture medium without Y-27632, the culture medium comprising the following components: 1% penicillin-streptomycin-amphotericin B, 1 mM Sodium Pyruvate, 25 mM HEPES, 20 mM GlutaMAX, 100 μg / mL Primocin, 20 nM 17-βestradiol, 500 ng / mL Hydrocortisone, 5 μM A83-01, 5 μM Nicotinamide, 10 mL / L N-2 supplement, 20 mL / L B-27 supplement, 1.25 mM N-acetylcysteine, 0.5 μM Adezmapimod, 20 ng / mL EGF, 100 ng / mL FGF-10, 100 ng / mL Noggin, 250 ng / mL R-spondin1, 50 ng / mL Heregulin-β-1, 100 ng / mL Wnt3a, 5 μM Forskolin, the above components were dissolved in Advanced DMEM / F12.
[0036] Use the prepared reagents and culture medium to complete the construction of organoids from ovarian cancer puncture samples. The specific steps are as follows:
[0037] (1) After the biopsy sample is removed from the body, it is washed with 5 times the sample volume of ovarian cancer puncture sample preservation solution, then transferred to 10 times the sample volume of sample preservation solution, transported in a cold chain at 0-8℃, and transported to the laboratory within 24 hours;
[0038] (2) Remove the sample, immerse it in sterile 0.4% trypan blue staining solution for 1 min, and then remove the stained non-viable cell tissue;
[0039] (3) Transfer the puncture sample that has not been stained with 0.4% trypan blue staining solution to 10 times the volume of sample cleaning solution and place it in a constant temperature shaker at 25°C, 200 rpm, for 60-90 min. Replace the sample cleaning solution every 5 min and collect the cleaning solution that is replaced each time;
[0040] (4) 500 × g, 4°C, 10 min, centrifuge to collect the replaced sample wash solution and the precipitate at the bottom of the tube;
[0041] (5) After washing, the loose and soft tumor sample was collected by centrifugation and filtered through a 100 μm filter together with the precipitate collected by centrifugation;
[0042] (6) 500 × g, 4°C, 10 min, discard the supernatant, collect the sample precipitate, add ovarian cancer organoid culture medium to form a cell suspension, mix it thoroughly with Matrigel, and evenly drip 30-40 μL / drop into the well plate;
[0043] (7) Place in a 37°C incubator for 30 min to allow the matrix gel to fully solidify;
[0044] (8) Remove the culture plate, add ovarian cancer organoid culture medium, place it in an incubator and continue culturing for 24 hours, then replace it with ovarian cancer culture medium without Y-27632. After about 3 days, the formation of ovarian cancer organoid morphology can be observed;
[0045] (9) Incubate at 37°C and 5% CO2 for 7 to 20 days, changing the medium every 3 days;
[0046] (10) The morphology of organoids after 3 and 10 days of culture Figure 1 shown.
[0047] Example 2
[0048] The culture medium and cleaning solution used in this example are as follows:
[0049] (1) An ovarian cancer biopsy specimen preservation solution, comprising the following components: 15 μM Necrostatin-1, 25 mM GlutaMAX, and 1.5% penicillin-streptomycin-amphotericin B, wherein the above components are dissolved in Advanced DMEM / F12, prepared before use, and temporarily stored or transported at 0-8°C;
[0050] (2) An ovarian cancer biopsy sample cleaning solution, the cleaning solution comprising the following components: 2% penicillin-streptomycin-amphotericin B, 0.1 mg / mL DNaseⅠ, 5 mg / mL Dispase II, 10 μM Y-27632, the above components are dissolved in 1×DPBS and prepared before use;
[0051] (3) An ovarian cancer biopsy sample culture medium, the culture medium comprising the following components: 1% penicillin-streptomycin-amphotericin B, 1 mM Sodium Pyruvate, 10 mM HEPES, 30 mM GlutaMAX, 200 μg / mL Primocin, 10 nM 17-βestradiol, 500 ng / mL Hydrocortisone, 3 μM A83-01, 5 μM Nicotinamide, 10 mL / L N-2 supplement, 20 mL / L B-27 supplement, 1.25 mM N-acetylcysteine, 1 μM Adezmapimod, 10 ng / mL EGF, 80 ng / mL FGF-10, 200 ng / mL Noggin, 150 ng / mL R-spondin1, 50 ng / mL Heregulin-β-1, 100 ng / mL Wnt3a, 10 μM Forskolin, 10 μM Y-27632, the above components were dissolved in Advanced DMEM / F12;
[0052] (4) A Y-27632-free ovarian cancer biopsy sample culture medium, the culture medium comprising the following components: 1% penicillin-streptomycin-amphotericin B, 1 mM Sodium Pyruvate, 10 mM HEPES, 30 mM GlutaMAX, 200 μg / mL Primocin, 10 nM 17-βestradiol, 500 ng / mL Hydrocortisone, 3 μM A83-01, 5 μM Nicotinamide, 10 mL / L N-2 supplement, 20 mL / L B-27 supplement, 1.25 mM N-acetylcysteine, 1 μM Adezmapimod, 10 ng / mL EGF, 80 ng / mL FGF-10, 200 ng / mL Noggin, 150 ng / mL R-spondin1, 50 ng / mL Heregulin-β-1, 100 ng / mL Wnt3a, 10 μM Forskolin, the above components were dissolved in Advanced DMEM / F12;
[0053] Use the prepared reagents and culture medium to complete the construction of organoids from ovarian cancer puncture samples. The specific steps are as follows:
[0054] (1) After the biopsy sample is removed from the body, it is washed with 5 times the sample volume of ovarian cancer puncture sample preservation solution, then transferred to 10 times the sample volume of sample preservation solution, transported in a cold chain at 0-8℃, and transported to the laboratory within 24 hours;
[0055] (2) Remove the sample, immerse it in sterile 0.4% trypan blue staining solution for 1 min, and then remove the stained non-viable cell tissue;
[0056] (3) Transfer the puncture sample that has not been stained with 0.4% trypan blue staining solution to 10 times the volume of sample cleaning solution and place it in a constant temperature shaker at 25°C, 200 rpm, for 60-90 min. Replace the sample cleaning solution every 5 min and collect the cleaning solution that is replaced each time;
[0057] (4) 500 × g, 4°C, 10 min, centrifuge to collect the replaced sample wash solution and the precipitate at the bottom of the tube;
[0058] (5) After washing, the loose and soft tumor sample was collected by centrifugation and filtered through a 100 μm filter together with the precipitate collected by centrifugation;
[0059] (6) 500 × g, 4°C, 10 min, discard the supernatant, collect the sample precipitate, add ovarian cancer organoid culture medium to form a cell suspension, mix it thoroughly with Matrigel, and evenly drip 30-40 μL / drop into the well plate;
[0060] (7) Place in a 37°C incubator for 30 min to allow the matrix gel to fully solidify;
[0061] (8) Remove the culture plate, add ovarian cancer organoid culture medium, place it in an incubator and continue culturing for 24 hours, then replace it with ovarian cancer culture medium without Y-27632. After about 3 days, the formation of ovarian cancer organoid morphology can be observed;
[0062] (9) Cultivate in a 37°C incubator for 7 to 20 days, changing the medium every 3 days;
[0063] (10) The morphology of organoids after 3 and 10 days of culture Figure 2 shown.
[0064] Comparative Example 1
[0065] (1) An ovarian cancer biopsy specimen preservation solution, the preservation solution comprising the following components: 1% penicillin-streptomycin-amphotericin B, the above components are dissolved in Advanced DMEM / F12, prepared before use, and temporarily stored or transported at 0-8°C;
[0066] (2) An ovarian cancer biopsy sample cleaning solution, the cleaning solution comprising the following components: 2% penicillin-streptomycin-amphotericin B, 0.2 mg / mL DNase I, 10 μM Y-27632, the above components are dissolved in 1×DPBS and prepared before use;
[0067] (3) An ovarian cancer biopsy sample culture medium, the culture medium comprising the following components: 1% penicillin-streptomycin-amphotericin B, 1mM Sodium Pyruvate, 25mM HEPES, 20mM GlutaMAX, 100μg / mL Primocin, 20nM 17-βestradiol, 500ng / mL Hydrocortisone, 5μM A83-01, 5μM Nicotinamide, 10mL / L N-2supplement, 20mL / L B-27supplement, 1.25mM N-acetylcysteine, 0.5μM Adezmapimod, 20ng / mL EGF, 100ng / mL FGF-10, 100ng / mL Noggin, 250ng / mL R-spondin1, 50ng / mL Heregulin-β-1, 100ng / mL Wnt3a, 5μM Forskolin, 10μM Y-27632, the above components were dissolved in AdvancedDMEM / F12;
[0068] (4) An ovarian cancer biopsy sample culture medium without Y-27632, the culture medium comprising the following components: 1% penicillin-streptomycin-amphotericin B, 1 mM Sodium Pyruvate, 25 mM HEPES, 20 mM GlutaMAX, 100 μg / mL Primocin, 20 nM 17-βestradiol, 500 ng / mL Hydrocortisone, 5 μM A83-01, 5 μM Nicotinamide, 10 mL / L N-2 supplement, 20 mL / L B-27 supplement, 1.25 mM N-acetylcysteine, 0.5 μM Adezmapimod, 20 ng / mL EGF, 100 ng / mL FGF-10, 100 ng / mL Noggin, 250 ng / mL R-spondin1, 50 ng / mL Heregulin-β-1, 100 ng / mL Wnt3a, 5 μM Forskolin, the above components were dissolved in Advanced DMEM / F12;
[0069] Organoid construction of ovarian cancer biopsy samples was completed using reagents and culture medium prepared in comparative proportions;
[0070] (1) After the biopsy sample is removed from the body, it is washed with 5 times the sample volume of ovarian cancer puncture sample preservation solution, then transferred to 10 times the sample volume of sample preservation solution, transported in a cold chain at 0-8℃, and transported to the laboratory within 24 hours;
[0071] (2) Remove the sample, immerse it in sterile 0.4% trypan blue staining solution for 1 min, and then remove the stained non-viable cell tissue;
[0072] (3) Transfer the puncture sample that has not been stained with 0.4% trypan blue staining solution to 10 times the volume of sample cleaning solution and place it in a constant temperature shaker at 25°C, 200 rpm, for 60-90 min. Replace the sample cleaning solution every 5 min and collect the cleaning solution that is replaced each time;
[0073] (4) 500 × g, 4°C, 10 min, centrifuge to collect the replaced sample wash solution and the precipitate at the bottom of the tube;
[0074] (5) After washing, the loose and soft tumor sample was collected by centrifugation and filtered through a 100 μm filter together with the precipitate collected by centrifugation;
[0075] (6) 500 × g, 4°C, 10 min, discard the supernatant, collect the sample precipitate, add ovarian cancer organoid culture medium to form a cell suspension, mix it thoroughly with Matrigel, and evenly drip 30-40 μL / drop into the well plate;
[0076] (7) Place in a 37°C incubator for 30 min to allow the matrix gel to fully solidify;
[0077] (8) Remove the culture plate, add ovarian cancer organoid culture medium, place it in an incubator and continue culturing for 24 hours, then replace it with ovarian cancer culture medium without Y-27632. After about 3 days, the formation of ovarian cancer organoid morphology can be observed;
[0078] (9) Cultivate in a 37°C incubator for 7 to 20 days, changing the medium every 3 days;
[0079] (10) The morphology of organoids after 3 and 10 days of culture is shown in Figure 1. Figure 3 .
[0080] The present invention can quickly and efficiently construct a large number of ovarian cancer organoids from ovarian cancer puncture samples without the need for separate digestion and enzymatic hydrolysis. Compared with traditional organoid construction technology, it improves the construction efficiency and quantity of ovarian cancer puncture sample organoids.
[0081] Comparing the culture results of the above three schemes, we can conclude that:
[0082] Compared with the organoids cultured in the scheme described in Comparative Example 1 (such as Figure 3 Compared with Example 1 (as shown in Figure 1 As shown) and Example 2 (as Figure 2 In the culture scheme shown in Figure 2, in the same size of the field of view, the number of organoids formed was large and the state was good, and most of the organoids were solid; while in Comparative Example 1, the number of organoids formed was significantly small, and most of them were vacuolated. After subsequent passage, the growth rate of the organoids was significantly slowed down, and the state of the organoids was also poor;
[0083] Comparing the culture effects of Examples 1 and 2, there was no significant difference in the organoid morphology, but the number of organoids formed in Example 1 was greater.
[0084] Therefore, the culture medium in Example 1 has a better culture effect.
[0085] The number of organoids of the three schemes under the same size field of view (total magnification 100 times) was counted (average of 6 fields of view), as shown in Table 1 below:
[0086]
[0087]
[0088] The results show that Example 1 has the largest number of organoids, indicating that the culture conditions are optimal.
[0089] The above-described embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by those skilled in the art based on the present invention are within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.
Claims
1. A composition for constructing organoids based on clinical puncture samples of ovarian cancer, characterized in that: The composition includes a sample preservation solution and a sample culture medium; The components of the sample preservation solution are as follows: 1-20 μM Necrostatin-1, 15-40 mM GlutaMAX, 0.5-3% penicillin-streptomycin-amphotericin B, and the balance is Advanced DMEM / F12; The components of the sample culture medium are as follows: 0.5-3mM Sodium Pyruvate, 10-50mM HEPES, 10-50mM GlutaMAX, 100-300μg / mL Primocin, 10-200nM 17-βestradiol, 200-1000ng / mL Hydrocortisone, 1-10μM A83-01, 1-10μM Nicotinamide, 5-30mL / L N-2supplement, 5-30mL / L B-27supplement, 1-3mM N-acetylcysteine, 0.1-2μM Adezmapimod, 5-100ng / mL EGF, 10-200ng / mL FGF-10, 50-200ng / mL Noggin, 50-250ng / mL R-spondin1, 20-200 ng / mL Heregulin-β-1, 50-500 ng / mL Wnt3a, 2-20 μM Forskolin, 5-20 μM Y-27632, 0.5-3% Penicillin-Streptomycin-Amphotericin B, the balance is Advaced DMEM / F12.
2. The composition for constructing organoids based on clinical ovarian cancer puncture samples according to claim 1, characterized in that: The sample washing solution is also included, and the concentrations of the components of the washing solution are as follows: 0.5-3% penicillin-streptomycin-amphotericin B, 0.05-0.5 mg / mL DNaseⅠ, 1-5 mg / mL Dispase II, 5-20 μM Y-27632, and the balance is 1×DPBS.
3. The composition for constructing organoids based on clinical ovarian cancer puncture samples according to claim 1, characterized in that: The components of the sample preservation solution are as follows: 1-20 μM Necrostatin-1, 15-40 mM GlutaMAX, 0.5-3% penicillin-streptomycin-amphotericin B, and the balance is Advanced DMEM / F12.
4. The composition for constructing organoids based on clinical ovarian cancer puncture samples according to claim 1, characterized in that: The components of the sample culture medium are as follows: 1mM Sodium Pyruvate, 10-25mM HEPES, 20-30mM GlutaMAX, 100-200μg / mL Primocin, 10-20nM 17-βestradiol, 500ng / mL Hydrocortisone, 3-5μMA83-01, 5μM Nicotinamide, 10mL / L N-2supplement, 20mL / L B-27supplement, 1.25mM N-acetylcysteine, 0.5-1μM Adezmapimod, 20ng / mL EGF, 100~200ng / mL FGF-10, 100-200ng / mL Noggin, 50~250ng / mL R-spondin1, 50ng / mL Heregulin-β-1, 100ng / mL Wnt3a, 5-10 μM Forskolin, 10 μM Y-27632, 1% Penicillin-Streptomycin-Amphotericin B, and the balance was Advanced DMEM / F12.
5. A method for constructing an organoid using the composition according to any one of claims 1 to 4, characterized in that , the specific method is as follows: (1) After taking an ovarian cancer biopsy sample from the body, the sample is washed with a cleaning solution and then preserved with a preservation solution; (2) staining the preserved sample with trypan blue staining solution, removing the stained non-living cell tissue, transferring the unstained puncture sample to the sample cleaning solution, shaking and cleaning, changing the cleaning solution during the process, and collecting the cleaning solution at the same time; (3) centrifuging the collected washing solution and collecting the precipitate at the bottom of the tube; (4) After washing, collect the loose and soft tumor sample by centrifugation and filter it with the precipitate obtained in step (3) through a 100 μm filter; (5) Centrifuge and discard the supernatant, collect the sample precipitate, add the sample culture medium to form a cell suspension, mix it thoroughly with Matrigel, and drip it into the well plate; let it stand and culture to allow the matrix gel to fully solidify, then add the sample culture medium and culture it for 24 hours, then add the sample culture medium without Y-27632, change the medium every 3 days, and culture until ovarian cancer organoids are formed.
6. The method according to claim 5, characterized in that: Step (1) is to wash the biopsy sample with a washing solution 5 times the sample volume after the sample is removed from the body, and then transfer the sample to a sample preservation solution 10 times the sample volume and transport it at a cold chain of 0-8°C.
7. The method according to claim 5, characterized in that: In step (2), the concentration of the trypan blue staining solution is 0.4%, and the staining time is 1 min.
8. The method according to claim 5, characterized in that: In step (2), the shaking cleaning is carried out at 25° C., 200 rpm, and 60-90 min, and the sample cleaning solution is replaced every 5 min.
9. The method according to claim 5, characterized in that: In step (4) and step (5), the centrifugation is 500×g, 4° C., 10 min.
